[Federal Register: August 9, 2007 (Volume 72, Number 153)]
[Notices]
[Page 44860-44861]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr09au07-87]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 29, 2007, Chattem
Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by letter to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following
[[Page 44861]]
basic classes of controlled substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Lisdexamfetamine (1205).................... II
Remifentanil (9739)........................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR
1301.33(a). Any such comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537; or any being sent via
express mail should be sent to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be
filed no later than October 9, 2007.
Dated: July 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-15499 Filed 8-8-07; 8:45 am]
BILLING CODE 4410-09-P